Our study identified a novel long noncoding RNA, LINC01322, that acts as an oncogene in lung adenocarcinoma progression. Cytoplasmic and nuclear RNA purification assays indicated that LINC01322 was localized in the cytoplasm and nucleus. Gene set enrichment analysis revealed the involvement of LINC01322 in the regulation of cell proliferation, migration, and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. LINC01322 may promote lung adenocarcinoma proliferation and migration through the Janus kinase/signal transducer and activator of transcription signaling pathway. experiments demonstrated that the knockdown of LINC01322 significantly suppressed lung adenocarcinoma cell proliferation, migration, and activation of the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway, whereas overexpression had the opposite effects. Inhibition of the Janus kinase 2/signal transducer and activator of transcription 3 pathway activity partially reversed the enhancement of cell proliferation and migration caused by LINC01322 overexpression. experiments further verified the oncogene role of LINC01322. Altogether, our findings suggest that LINC01322 promotes lung adenocarcinoma progression by activating the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway and that it could be a therapeutic target.

中文翻译：

---

LINC01322 作为潜在的预后生物标志物和促进肺腺癌肿瘤进展的癌基因的鉴定和验证

我们的研究发现了一种新型长非编码 RNA，LINC01322，它在肺腺癌进展中充当癌基因。细胞质和核 RNA 纯化测定表明 LINC01322 定位于细胞质和细胞核。基因集富集分析揭示了 LINC01322 参与细胞增殖、迁移以及 Janus 激酶/信号转导器和转录激活剂 (JAK/STAT) 信号通路的调节。LINC01322可能通过Janus激酶/信号转导器和转录信号通路激活剂促进肺腺癌增殖和迁移。实验表明，LINC01322的敲低显着抑制了肺腺癌细胞的增殖、迁移以及Janus激酶2/信号转导子和转录激活子3信号通路的激活，而过表达则具有相反的效果。Janus 激酶 2/信号转导器和转录激活剂 3 通路活性的抑制部分逆转了 LINC01322 过表达引起的细胞增殖和迁移的增强。实验进一步验证了LINC01322的致癌基因作用。总而言之，我们的研究结果表明，LINC01322 通过激活 Janus 激酶 2/信号转导器和转录激活剂 3 信号通路来促进肺腺癌进展，并且它可能是一个治疗靶点。